Regeneron Pharmaceuticals, Inc. financial data

Symbol
REGN on Nasdaq
Industry
Pharmaceutical Preparations
Location
777 Old Saw Mill River Road, Tarrytown, NY
State of incorporation
NY
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Oct 31, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 542 % +2.57%
Quick Ratio 78.9 % +3.23%
Debt-to-equity 27.6 % -2.89%
Return On Equity 16.9 % +0.36%
Return On Assets 13.2 % +0.99%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 76.7B USD +23.7%
Weighted Average Number of Shares Outstanding, Basic 108M shares +1.69%
Weighted Average Number of Shares Outstanding, Diluted 116M shares +2.47%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 13.8B USD +5.73%
Research and Development Expense 4.9B USD +13.8%
Costs and Expenses 9.87B USD +11.2%
Operating Income (Loss) 3.97B USD -5.87%
Nonoperating Income (Expense) 996M USD +541%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 4.97B USD +13.6%
Income Tax Expense (Benefit) 315M USD -18.3%
Net Income (Loss) Attributable to Parent 4.65B USD +16.6%
Earnings Per Share, Basic 43.2 USD/shares +15.7%
Earnings Per Share, Diluted 40.4 USD/shares +15.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.01B USD -6.53%
Marketable Securities, Current 7.78B USD +0.3%
Accounts Receivable, after Allowance for Credit Loss, Current 6.11B USD +9.36%
Inventory, Net 3.02B USD +17.8%
Assets, Current 19.3B USD +3.75%
Deferred Income Tax Assets, Net 3.02B USD +30.1%
Property, Plant and Equipment, Net 3.7B USD +9.09%
Operating Lease, Right-of-Use Asset 78M USD +9.55%
Intangible Assets, Net (Excluding Goodwill) 1.12B USD +10.1%
Other Assets, Noncurrent 1.04B USD +154%
Assets 37.4B USD +16.4%
Accounts Payable, Current 497M USD -7.32%
Employee-related Liabilities, Current 618M USD +24.3%
Contract with Customer, Liability, Current 627M USD +50.3%
Liabilities, Current 3.66B USD +1.73%
Contract with Customer, Liability, Noncurrent 207M USD +65.5%
Operating Lease, Liability, Noncurrent 68.7M USD +23.1%
Other Liabilities, Noncurrent 1.54B USD +85.4%
Liabilities 8.12B USD +11.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 60.2M USD
Retained Earnings (Accumulated Deficit) 30.8B USD +17.8%
Stockholders' Equity Attributable to Parent 29.3B USD +17.8%
Liabilities and Equity 37.4B USD +16.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 1.51B USD +10.6%
Net Cash Provided by (Used in) Financing Activities 47.1M USD
Net Cash Provided by (Used in) Investing Activities -1.69B USD -616%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -128M USD -116%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.01B USD -6.87%
Deferred Tax Assets, Gross 2.63B USD +47.4%
Operating Lease, Liability 87.7M USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 4.89B USD +19.6%
Lessee, Operating Lease, Liability, to be Paid 103M USD
Operating Lease, Liability, Current 19M USD +53.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 20.1M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 24.1M USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 15.6M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 15.6M USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30M shares 0%
Unrecognized Tax Benefits 696M USD +28.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 12.4M USD
Additional Paid in Capital 12.7B USD +12.9%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 37.6M USD
Depreciation, Depletion and Amortization 114M USD +14.7%
Interest Expense 71.1M USD +11.4%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%